Efficacy of folic acid supplementation in stroke prevention: New insight from a meta-analysis

International Journal of Clinical Practice

Volumn 66, Issue 6, 2012, Pages 544-551

  Huo, Yong ^a   Qin, X ^b   Wang, J ^c   Sun, N ^d   Zeng, Q ^e   Xu, X ^b,f   Liu, L ^g   Wang, Xiaobin ^h  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^e CHINESE PLA GENERAL HOSPITAL   (China)

^f SOUTHERN MEDICAL UNIVERSITY   (China)

^g FUWAI HOSPITAL   (China)

^h JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; CYANOCOBALAMIN; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OMEGA 3 FATTY ACID; PLACEBO; PYRIDOXINE; VITAMIN B GROUP;

ARTICLE; DOSE RESPONSE; DRUG EFFICACY; EFFECT SIZE; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RISK REDUCTION; STROKE; SUPPLEMENTATION; SYSTEMATIC REVIEW;

AGED; DIETARY SUPPLEMENTS; FEMALE; FOLIC ACID; HEMATINICS; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STROKE;

EID: 84861320670     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2012.02929.x     Document Type: Article

References (45)

1. Holmes MV, Newcombe P, Hubacek JA, et al., Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet 2011; 378: 584-94.
2. Wang X, Qin X, Demirtas H, et al., Lancet 2007; 369: 1876-82.
3. Lee M, Hong KS, Chang SC, Saver JL,. Efficacy of homocysteine-lowering therapy with folic acid in stroke prevention: a meta-analysis. Stroke 2010; 41: 1205-12.
4. Qin X, Huo Y, Langman CB, et al., Folic acid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol 2011; 6: 482-88.
5. Qin X, Xu M, Zhang Y, et al., Effect of folic acid supplementation on the progression of carotid intima-media thickness: a meta-analysis of randomized controlled trials. Atherosclerosis 2011. [Epub ahead of print].
6. Clarke R, Halsey J, Lewington S, et al., Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of eight randomized trials involving 37,485 individuals. Arch Intern Med 2010; 170: 1622-31.
7. Heinz J, Kropf S, Domröse U, et al., B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial. Circulation 2010; 121: 1432-38.
8. Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S,. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ 2010; 341: c6273.
9. Bostom AG, Carpenter MA, Kusek JW, et al., Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the folic acid for vascular outcome reduction in transplantation trial. Circulation 2011; 123: 1763-70.
10. Moher D, Liberati A, Tetzlaff J, Altman DG,; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRIsMa statement. Ann Intern Med 2009; 151: 264-69.
11. Moher D, Pham B, Jones A, et al., Does quality of reports of randomized trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352: 609-13.
12. Higgins JP, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.
13. Lange H, Suryapranata H, De Luca G, Dambrink JHE,. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 2004; 350: 2673-81.
14. Righetti M, Ferrario GM, Milani S, Sessa A,. Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients. Med Sci Monit 2003; 9: PI19-24.
15. Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM,. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart Study: a randomized controlled trial. JAMA 2002; 288: 973-79.
16. Vianna AC, Mocelin AJ, Matsuo T, Matni AM,. Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events. Hemodial Int 2007; 11: 210-16.
17. Baker F, Picton D, Blackwood S, Brown MJ,. Blinded comparison of folic acid and placebo in patients with ischaemic heart disease: an outcome trial. Circulation 2002; 106 (Suppl. 2): 741.
18. den Heijer M, Willems HP, Blom HJ, et al., Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial. Blood 2007; 109: 139-44.
19. Imasa MS, Gomez NT, Nevado JB Jr,. Folic acid-based intervention in non-ST elevation acute coronary syndromes. Asian Cardiovasc Thorac Ann 2009; 17: 13-21.
20. House AA, Eliasziw M, Cattran DC, et al., Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA 2010; 303: 1603-09.
21. Liem AH, van Boven AJ, Veeger NJ, Withagen AJ, van Veldhuisen DJ,. Efficacy of folic acid when added to statin therapy in patients with hypercholesterolemia following acute myocardial infarction: a randomized pilot trial. Int J Cardiol 2004; 93: 175-79.
22. Righetti M, Serbelloni P, Milani S, Ferrario G,. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood Purif 2006; 24: 379-86.
23. Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, Jukema JW, van Veldhuisen DJ,. Secondary prevention with folic acid: effects on clinical outcomes. J Am Coll Cardiol 2003; 41: 2105-13.
24. Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, Jukema JW, van Veldhuisen DJ,. Secondary prevention with folic acid: results of the Goes extension study. Heart 2005; 91: 1213-14.
25. Armitage JM, Bowman L, Clarke RJ, et al., Effects of homocysteine- lowering with folic acid plus vitamin B12 vs. placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. JAMA 2010; 303: 2486-94.
26. VITATOPS Trial Study Group. B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. Lancet Neuro 2010; 9: 855-65.
27. Toole JF, Malinow MR, Chambless LE, et al., Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291: 565-75.
28. Mark SD, Wang W, Fraumeni JF Jr, et al., Lowered risks of hypertension and cerebrovascular disease after vitamin/mineral supplementation: the Linxian Nutrition Intervention. Am J Epidemiol 1996; 143: 658-64.
29. Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP,. Randomized trial of folic acid for prevention of cardiovascular events in end stage renal disease. J Am Soc Nephrol 2004; 15: 420-26.
30. Bønaa KH, Njølstad I, Ueland PM, et al., Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006; 354: 1578-88.
31. Lonn E, Yusuf S, Arnold MJ, et al., Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354: 1567-77.
32. Zoungas S, McGrath BP, Branley P, et al., Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J Am Coll Cardiol 2006; 47: 1108-16.
33. Jamison RL, Hartigan P, Kaufman JS, et al., Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end stage renal disease: a randomized controlled trial. JAMA 2007; 298: 1163-70.
34. Albert CM, Cook NR, Gaziano JM, et al., Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA 2008; 299: 2027-36.
35. Ebbing M, Bleie O, Ueland PM, et al., Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA 2008; 300: 795-804.
36. Wald DS, Law M, Morris JK,. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325: 1202-06.
37. Wald DS, Wald NJ, Morris JK, Law M,. Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. BMJ 2006; 333: 1114-17.
38. Saposnik G, Ray JG, Sheridan P, McQueen M, Lonn E,. Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke 2009; 40: 1365-72.
39. Jacques PF, Selhub J, Bostom AG, Wilson PWF, Rosenberg IH,. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999; 340: 1449-54.
40. Homocysteine Lowering Trialists' Collaboration. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J Clin Nutr 2005; 82: 806-12.
41. Spence JD,. Homocysteine-lowering therapy: a role in stroke prevention? Lancet Neurol 2007; 6: 830-38.
42. Hirche F, Schroder A, Knoth B, Stangl GI, Eder K,. Methionine induced elevation of plasma homocysteine concentration is associated with an increase of plasma cholesterol in adult rats. Ann Nutr Metab 2006; 50: 139-46.
43. Liao D, Tan H, Hui R, et al., Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I protein synthesis and enhancing HDL cholesterol clearance. Circ Res 2006; 99: 598-606.
44. Qin X, Li J, Cui Y, et al., Effect of folic acid intervention on the change of serum folate level in hypertensive Chinese adults: do methylenetetra-hydrofolate reductase and methionine synthase gene polymorphisms affect therapeutic responses? Pharmacogenet Genomics 2011. [Epub ahead of print].
45. Qin X, Li J, Cui Y, et al., MTHFR C677T and MTR A2756G polymorphisms and the homocysteine lowering efficacy of different doses of folic acid in hypertensives Chinese adults. Nutr J 2012; 11: 2.